| Makale Türü |
|
||
| Dergi Adı | Springerplus | ||
| Dergi ISSN | 2193-1801 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 12-2014 |
| Kabul Tarihi | 06-11-2014 | Yayınlanma Tarihi | 01-12-2014 |
| Cilt / Sayı / Sayfa | 3 / 1 / 1–5 | DOI | 10.1186/2193-1801-3-725 |
| Makale Linki | http://www.springerplus.com/content/3/1/725 | ||
| UAK Araştırma Alanları |
Üroloji
|
||
| Özet |
| The first-line management of metastatic prostate cancer is hormonal therapy. However, resistance to this treatment will emerge within an average of 24 months. Our purpose was to determine the course of metastatic prostate cancer under treatment.A total of 56 patients who were diagnosed with metastatic prostate cancer were enrolled. As initial management, 3 kinds of hormonal therapy consisting of bilateral orchiectomy (BSO) alone, BSO + anti-androgene (AA) and LH-RH + AA were applied. The patients were followed until the emergence of hormone resistance. Serum PSA levels at the time of first diagnosis, post-treatment nadir PSA levels, time to nadir PSA, time to hormonal resistance and PSA levels at hormonal resistance were assessed, retrospectively. The localization and number of metastases and the survival term from the beginning of the emergence of hormone resistance until death were investigated … |
| Anahtar Kelimeler |
| Course | Metastatic prostate cancer | Treatment modality |
| Atıf Sayıları | |
| Web of Science | 4 |
| Scopus | 6 |
| Google Scholar | 9 |
| Dergi Adı | SpringerPlus |
| Yayıncı | Springer Science and Business Media Deutschland GmbH |
| Açık Erişim | Hayır |
| ISSN | 2193-1801 |
| E-ISSN | 2193-1801 |
| CiteScore | 3,4 |
| SJR | 0,125 |
| SNIP | 1,475 |